Markets:

Overview

News

Currencies

International

Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.04 +0.48 (+2.93%)

Streaming Delayed Price Updated: 2:14 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

What 4 Analyst Ratings Have To Say About Bausch & Lomb ↗

September 12, 2022

Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter:

Via Benzinga

Expert Ratings for Bausch & Lomb ↗

September 12, 2022

Within the last quarter, Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022 ↗

September 12, 2022

Upgrades

Via Benzinga

From Corporate Raider To Activist Investor: Here Are Three High-Yielding Stocks Carl Icahn Favors ↗

August 28, 2022

Formerly known as a "corporate raider," Carl Icahn is the founder and controlling shareholder of Icahn Enterprises, which is a large holding company with well diversified positions.

Via Benzinga

Expert Ratings for Bausch & Lomb ↗

August 16, 2022

Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter:

Via Benzinga

'Well-Established' Eye Health Company Bausch + Lomb Gets Outperform Rating From This Analyst ↗

July 26, 2022

Via Benzinga

Expert Ratings for Bausch & Lomb ↗

July 26, 2022

Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter:

Via Benzinga

BHC Stock Continues to Fall as Bausch Health Responds to Court Decision ↗

July 29, 2022

Although Bausch Health promises to fight back against an unfavorable patent protection ruling, BHC stock is still hurting.

Via InvestorPlace

Bausch Health (BHC) Stock Plunges 50% on Patent News ↗

July 28, 2022

With Bausch Health losing a critical patent battle enabling its key drug to suffer generic competition, BHC stock veritably crumbled.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

July 28, 2022

On Thursday, 108 companies set new 52-week lows.

Via Benzinga

IPO Market Posts Slowest Quarter Since Great Recession ↗

June 24, 2022

IPOs in the second quarter plunged to the lowest level since the Great Recession in 2009, led by health care and technology.

Via Investor's Business Daily

Why Shares of Solar Companies Are Trading Higher? 64 Stocks Moving In Thursday's Mid-Day Session ↗

July 28, 2022

Gainers

Via Benzinga

Meta, Charter Communications, Southwest Airlines And Some Other Big Stocks Moving Lower On Thursday ↗

July 28, 2022

Bausch Health Companies Inc. (NYSE: BHC) shares fell 50.3% to $4.3166 following reports of an order on a patent litigation over Xifaxan.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022 ↗

July 26, 2022

Upgrades

Via Benzinga

7 Ways to Prepare for a Recession: An Investor’s Guide ↗

June 24, 2022

There are plenty of ways to prepare for a recession. Here are seven ways you can make sure you're ready for whatever comes next.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗

June 24, 2022

Upgrades

Via Benzinga

2 Cheap Stocks Trading at “Deal of the Century” Prices ↗

June 10, 2022

Simple value metrics are provenly bad at generating consistent returns, but that doesn't mean there aren't opportunities to be found.

Via InvestorPlace

Expert Ratings for Bausch & Lomb ↗

June 09, 2022

Over the past 3 months, 7 analysts have published their opinion on Bausch & Lomb (NYSE:BLCO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

3 Value Stocks That Could 2x in a Recession ↗

June 02, 2022

It might be tempting to say that valuation metrics are no longer useful for certain kinds of value stocks, but you need to adjust your focus.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022 ↗

May 31, 2022

Upgrades

Via Benzinga

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More ↗

May 30, 2022

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022 ↗

May 11, 2022

Upgrades

Via Benzinga

Bausch Health (BHC) Stock Plunges 25% After Bausch + Lomb IPO ↗

May 10, 2022

Bausch Health (BHC) stock is falling on Tuesday following the release of its earnings report for the first quarter of 2022.

Via InvestorPlace

RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow ↗

May 09, 2022

RBC Capital Markets expects Bausch Health Companies Inc (NYSE: BHC) Q1 FY22 revenue of $2.02 billion (previous $2.04 billion; consensus $2.05 billion) and adjusted EBITDA of $799 million (previous $816...

Via Benzinga

Opening Day: Bausch + Lomb Pops In Public Debut ↗

May 07, 2022

Shares of Bausch + Lomb rose over 11% to end its first trading day at $20. This was the second biggest IPO of the year. Bausch + Lomb opened at $18.50 after having priced its initial public offering at...

Via Talk Markets

BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today ↗

May 06, 2022

Here's what investors in Bausch + Lomb may want to know about the highly anticipated BLCO stock IPO, which took place today.

Via InvestorPlace

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.